Sign In
Buy ATAI
$4.97
-0.200 (-3.87%)
At Close: Jul 13, 2026
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech
06:40am, Saturday, 03'rd Jul 2021
It's off to a running start.
5 Stocks With High Insider Interest
09:40pm, Thursday, 01'st Jul 2021
Unique insider buys at high levels through the second quarter
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
04:59pm, Friday, 18'th Jun 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics se
Peter Thiel-backed psychedelic start-up's shares pop in Wall Street debut
02:30pm, Friday, 18'th Jun 2021
The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.
Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares
02:21pm, Friday, 18'th Jun 2021
Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.
Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut
02:02pm, Friday, 18'th Jun 2021
Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization
Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut
12:16pm, Friday, 18'th Jun 2021
(Reuters) -Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capital
Atai Life Sciences founder on using psychedelics to treat mental illness
10:13am, Friday, 18'th Jun 2021
Atai Life Sciences, a biotech company that uses psychedelics to treat mental illness, is going public on the Nasdaq Friday. Christian Angermayer, Atai Life Sciences founder, joined "Squawk Box" on Fri
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
11:21pm, Thursday, 17'th Jun 2021
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
